You are here

Journal of Pharmacy Practice

Journal of Pharmacy Practice

eISSN: 15311937 | ISSN: 08971900 | Current volume: 35 | Current issue: 5 Frequency: Bi-monthly
Journal of Pharmacy Practice (JPP) is a peer-reviewed journal that offers practicing pharmacists in-depth useful reviews and research trials and surveys of new drugs and novel therapeutic approaches, pharmacotherapy reviews and controversies, pharmacokinetics, drug interactions, drug administration, adverse drug events, medication safety, pharmacy education, and other pharmacy practice topics. Several issues will be partially dedicated to a pharmacy practice theme such as medication therapy management or drug-induced diseases. Special sections include biomedical informatics reviews, cardiology key articles, and the New York State Council of Health-System Section.

Like the pharmacy profession, topics are diverse. Recent topics have included:

  • Anticoagulation—Treating Thrombosis in Selected Patient Populations
  • Anticoagulation—Dosing, Monitoring, and Adverse Drug Reactions
  • Immunology and Autoimmune Diseases
  • Infectious Diseases in the Critically III
  • Diabetes Management
  • Topics in Internal Medicine
  • Hepatitis
  • Hepatology
  • Cardiovascular Therapeutics
  • Rheumatology

    Each peer-reviewed issue assesses practice issues; practice settings; therapeutics issues; disease management; the latest research; current government, legal and regulatory issues; as well as issues arising from today’s topsy-turvy health-care environment. Each issue features a guest editor with particular expertise in the subject area.


     Journal Specialty Sections

    In addition to the main topic review articles, most issues will contain an Adverse Drug Events Section, Drug Information Section, Pharmacy Experiential Education Section, Law and Ethics in Pharmacy Practice Section, and a Biomedical Communications and Informatics Reviews Section.

    The Adverse Drug Events Section will review drug-induced adverse effect case reports, plausible mechanisms, a literature review, and recommendations for management and prevention.

    The Drug Information Section will provide the practitioner with comprehensively searched and evidence-based answers to a variety of drug information questions posed by health care professionals. A search strategy by drug information specialists will be provided to the audience.
    The Pharmacy Education Section will provide contemporary reviews addressing the challenges and innovations associated with providing quality learning experiences for students enrolled in pharmacy experiential education activities. It will offer recommendations/ suggestions for individuals who serve as experiential pharmacy preceptors. Potential topics will be selected by a nationally recognized group of pharmacy practitioners involved in experiential education and will address academic, administrative, and accreditation-related issues.

    The Law and Ethics in Pharmacy Practice Section will analyze pharmacy law, statutes and regulations, public policy, and ethical dilemmas as it pertains to pharmacy and health care.
    The Biomedical Communications and Informatics Reviews Section will thoroughly review new books, journals, drug information resources, and Web sites. Occasionally, research articles, special feature articles, editorials, and commentaries will be published.

    Journal Submissions

    Journal of Pharmacy Practice welcomes submissions for all journal sections including the Adverse Drug Events Section, Drug Information Section, Pharmacy Education Section, Law and Ethics in Pharmacy Practice Section, and Biomedical Communications and Informatics Reviews Section—section editors should be contacted directly for guidelines and submissions. Unsolicited manuscripts including research articles, commentaries, andother reports will also be considered for publication and should be submitted to the Editor-In-Chief.

    This journal is a member of the Committee on Publication Ethics (COPE).

Journal Aims

Journal of Pharmacy Practice is a peer-reviewed journal that was established in 1988 and is published 6 times per year. The journal is read and cited both nationally and internationally. The objective of the editorial board of the JPP, as well as that of SAGE Publications, is to offer the practicing pharmacist topical, pertinent, and useful information to support pharmacy practice and medication therapy management, as well as to expand the pharmacist's professional horizons. JPP is presented in a focused single-topic, scholarly, peer-review format. Guest editors are selected for particular expertise in the subject area; they then recruit consulting editors and contributors from that practice or topic area and bring the information together in a relevant and timely fashion for the pharmacist audience.

Journal Scope

The readership, like the pharmacy profession, is diverse and so are the topics covered in every issue. Since the walls between pharmacy practice sites remain distinct yet continue to blend in the continuum of care, each pharmacy practitioner needs to be primed on a wide variety of practice essentials, new advents, and future trends. By focusing on a single topic in each issue, the journal provides the reader with a thorough review of that topic written by experienced and accomplished practitioners. Practice issues, practice settings, therapeutics issues, disease management, research, government, legal, and regulatory issues are reviewed in a timely manner. Each issue contains a list of forthcoming topics.

We intend that the JPP will be of practical value to you. It has been used in daily practice as an informational reference and for teaching purposes; the focused, concise information provided saves time in literature review and provides a consolidated source of information and opinion for topics that affect the profession of pharmacy and the patients that pharmacists serve. Each issue will thoroughly review a topic, providing a validating experience for the reader who is familiar with the topic and new applicable knowledge for the reader who is not—validating for the expert, educating for the novice. Every effort has been made to ensure the correct usage of generic and trade names and to verify drug doses. The ultimate responsibility, however, lies with the practitioner. Please convey any errors or comments to the Editor-In-Chief.

Editor in Chief
Henry Cohen, MS, PharmD, BCPP, BCGP Touro College of Pharmacy, New York, NY, USA
Founding Editor
James T. O'Donnell Rush Medical College, Palatine, IL, USA
Managing and Scientific Editor
Catherine A. Millares-Sipin, Pharm.D., CGP, BCPS, BCACP Touro College of Pharmacy, New York, NY, USA
Adverse Drug Events Section
Sudha Narayanaswamy, BS, PharmD, BCPP, CGP GNYHA Services, Inc., New York, NY, USA
Roda Plakogiannis, BS, PharmD, BCPS, CLS Long Island University, Brooklyn, NY, USA
Biomedical Communications and Informatics Reviews Section
Peter D. Anderson, PharmD, BCPP, DABFE, FASCP University of Rhode Island, Kingston, RI, USA
Cardiology Key Articles
Christopher Ensor, PharmD, BCPS-CV University of Pittsburgh, Pittsburgh, PA, USA
Paul P. Dobesh, PharmD, FCCP, BCPS (AQ - Cardiology) University of Nebraska Medical Center, Omaha, NE, USA
Pharmacy Experiential Education
Joseph M. Brocavich, PharmD St. John's University, Jamaica, NY, USA
Richard O’Brocta, PharmD University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA
Ambulatory Care
April Von Allmen, PharmD Kingsbrook Jewish Medical Center, Brooklyn, NY, USA
Valery L. Chu, BS, PharmD Kingsbrook Jewish Medical Center, USA
John M. Conry, PharmD, BCPS, AAHIVP St. John's University, Jamaica, NY, USA
Robert V. DiGregorio, PharmD, BCACP, FNAP The Brooklyn Hospital Center, Brooklyn, NY, USA
Peter Dumo, PharmD Harper University Hospital, Detroit, MI, USA
Behavioral Health
Robert L. Dufresne, PhD, BCPS, BCPP University of Rhode Island College of Pharmacy, Kingston, RI, USA
John Noviasky, PharmD St. Elizabeth Medical Center, Utica, NY, USA
Brian R. Overholser, PharmD, FCCP College of Pharmacy, Purdue University, Indianapolis, IN, USA
Cynthia A. Sanoski, BS, PharmD, FCCP, BCPS University of the Sciences in Philadelphia, PA, USA
Clinical Pharmacology
Joseph A. Grillo, PharmD Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, USA
Critical Care
Erkan Hassan, PharmD, FCCM VISICU, Baltimore, MD, USA
Cheuk H. Liu, Pharm.D., BCNSP, BCPS Yale-New Haven Hospital, New Haven, CT, USA
Maria I. Rudis, PharmD, DABAT, FCCM University of Southern California, Los Angeles, CA, USA
Drug Information
Michael G. Kendrach, PharmD Samford University, Birmingham, AL, USA
Emergency Medicine
Joseph A. Barone, PharmD Rutgers-The State University of New Jersey, Piscataway, NJ, USA
George Delgado Jr., PharmD University Health Center, Detroit, MI, USA
Christine M. Stork, PharmD University Hospital, Syracuse, NY, USA
Martin D. Higbee, PharmD University of Arizona, Tucson, AZ, USA
Christine K. O'Neil, PharmD, BCPS, GCP, FCCP Duquesne University, Pittsburgh, PA, USA
Brian A. Hemstreet, PharmD, BCPS University of Colorado, Denver, CO, USA
HIV Disease
Agnes Cha, PharmD, AAHIVP, BCACP The Brooklyn Hospital Center, New York, NY, USA
Hélène Hardy, PharmD, Msc Boston Medical Center, Boston, MA, USA
Christopher W. James, PharmD Christiana Care Health Services, Wilmington, DE, USA
Infectious Disease
Ben M. Lomaestro, PharmD Albany College of Pharmacy, Albany, NY, USA
Vincent J. Peyko, PharmD, BCPS (AQ-ID) St. Elizabeth’s Boardman, Boardman, OH, USA
Kurt A. Wargo, PharmD, BCPS Auburn University, Auburn, AL, USA
Internal Medicine
Manouchkathe Cassagnol, PharmD, CGP, BCPS College of Pharmacy and Health Sciences, St. John’s University, Jamaica, NY, USA
Liya Davydov, BCPS, CGP Director, Clinical Pharmacy Services, Innovatix LLC, New York, NY, USA
Nino Marzella, MS, PharmD New York Harbor Healthcare System, Brooklyn, NY, USA
Joseph Reilly, Pharm.D. AtlantiCare Regional Medical Center, Pomona, NJ, USA
Elizabeth A. Stone, PharmD Good Samaritan Hospital, West Islip, NY, USA
Darko Todorov, Pharm.D., BCPS Kingsbrook Jewish Medical Center, Brooklyn, NY, USA
Toyin Tofade, MS, PharmD, BCPS UNC Eshelman School of Pharmacy, USA
International Pharmacy
Christine Mary Clark, BSc, MSc, PhD, FrPharmS Rossendale, Lancashire, UK
Jean G. Dib, BS Pharm, PharmD Dhahran Health Center, Pharmacy Services Division, Saudi Arabia
Laurence A. Goldberg, FRPharmS Hospital Pharmacy Europe, Lancashire, UK
Medication Safety
Elizabeth A. Shlom, PharmD, BCPS GNYHA Services, Inc., New York, NY, USA
Lisa Hall Zimmerman, PharmD, BCPS, BCNSP, FCCM New Hanover Regional Medical Center, Wilmington, NC, USA
Medication Therapy Management
Todd J. Woodard, Pharm.D., BCPP, BCPS, CGP Peach State Health Plan, Atlanta, GA, USA
Melanie S. Joy, PharmD University of North Carolina, Chapel Hill, NC, USA
Jack J. Chen, PharmD, FASCP, FCCP, FCPhA, BCPS, CGP College of Pharmacy, Marshall B. Ketchum University, Fullerton, CA, USA
Michael W. Jann, Pharm.D., FCP, FCCP University of North Texas Health Sciences Center, Forth Worth, TX, USA
Melody Ryan, PharmD, MPH University of Kentucky, Lexington, KY, USA
Nuclear Pharmacy
David L. Laven, NPh, CRPh, FASHP, FAPhA Gammascan Consultants, Longwood, FL, USA
Nutritional Support
Bishoy Luka, PharmD, BCNSP Queens Hospital Center, Jamaica, New York, USA
Alice C. Ceacareanu, PharmD, PhD School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, USA
Hien Nguyen, Pharm.D., BCPS AtlantiCare Regional Medical Center, Department of Pharmacy City Campus, Pomona, NJ, USA
Damary Torres, PharmD, BCOP St. John's University, Jamaica, NY, USA
Pain Management
Jeffrey Fudin, B.S., Pharm.D., FCCP Albany College of Pharmacy & Health Sciences, Albany, NY, USA
Ibis D. Lopez, PharmD, BCPS Morgan Stanley Children's Hospital of New York-Presbyterian, NY, USA
Betsy Bickert Poon, PharmD Florida Hospital for Children, USA
Charles Mahan, PharmD, PhC University of New Mexico, Albuquerque, NM, USA
Pharmacy Administration
Roy Guharoy, PharmD, MBA, FCP, FCCP, FASHP University of Massachusetts, Worcester, MA, USA
Pharmacy & Therapeutics
Gerry Barber, RPh, MPH, FASHP Department of Pharmacy Services, University of Colorado Hospital, Aurora, CO, USA
Manny Saltiel, Pharm.D, FASHP, FCCP Comprehensive Pharmacy Services, Los Angeles, CA, USA
Pharmacy Education
Eric G. Boyce, PharmD University of the Pacific, Stockton, CA, USA
James Colbert, PharmD University of California, San Diego, USA
Janet P. Engle, PharmD, PhD (Hon), FAPhA, FNAP University of Illinois, Chicago, IL, USA
Schwanda Flowers, PharmD University of Arkansas for Medical Sciences, USA
Philip Hritcko, PharmD University of Connecticut, USA
Denise Soltis, RPh Drake University, USA
Thomas Thompson, RPh Hamot Medical Center, USA
Pharmacy Law
Karl G. Williams, RPh, LLM, JD Saint John Fisher College, Rochester, NY, USA
Michael Biglow, PharmD, BCPS, BCPP Kingsbrook Jewish Medical Center, Brooklyn, NY, USA
Patty Ghazvini, PharmD Florida A&M University, Tallahassee, USA
W. Klugh Kennedy, PharmD, BCPP Mercer University, Macon, GA, USA
Dennis Williams, PharmD University of North Carolina, Chapel Hill, NC, USA
Geoffrey C. Wall, PharmD, BCPS, CGP Drake University, Des Moines, IA, USA
Steven Pass, PharmD, FCCM, FCCP, FASHP, BCPS Texas Tech University, Health Sciences Center School of Pharmacy, Lubbock, TX, USA
  • Academic Search - Premier
  • Academic Search Alumni Edition
  • Clarivate Analytics: Emerging Sources Citation Index (ESCI)
  • EBSCOhost: Academic Search Complete
  • EMBASE/Excerpta Medica
  • InfoTrac (full text)
  • ProQuest
  • ProQuest: International Pharmaceutical Abstracts
  • Scopus
  • This Journal is a member of the Committee on Publication Ethics.

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

    Please read the guidelines below then visit Journal of Pharmacy Practice (JPP)’s submission site to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.

    SAGE Publishing disseminates high-quality research and engaged scholarship globally, and we are committed to diversity and inclusion in publishing. We encourage submissions from a diverse range of authors from across all countries and backgrounds.

    Only manuscripts of sufficient quality that meet the aims and scope of JPP will be reviewed.

    There are no fees payable to submit or publish in this journal.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere. Please see our guidelines on prior publication and note that JPP may accept submissions of papers that have been posted on pre-print servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author may re-use their work according to the journal's author archiving policy. If your paper is accepted, you must include a link on your preprint to the final version of your paper.

    If you have any questions about publishing with SAGE, please visit the SAGE Journal Solutions Portal.


    1. What do we publish?
    1.1 Aims & Scope
    1.2 Article types
    1.3 Writing your paper

    2. Editorial policies
    2.1 Peer review policy
    2.2 Authorship
    2.3 Acknowledgements
    2.4 Funding
    2.5 Declaration of conflicting interests
    2.6 Research ethics and patient consent
    2.7 Clinical trials
    2.8 Reporting guidelines
    2.9 Research Data

    3. Publishing policies
    3.1 Publication ethics
    3.2 Contributor’s publishing agreement
    3.4 Open access and author archiving

    4. Preparing your manuscript
    4.1 Formatting
    4.2 Artwork, figures and other graphics
    4.3 Supplemental material
    4.4 Reference style
    4.5 English language editing services

    5. Submitting your manuscript
    5.1 ORCID
    5.2 Information required for completing your submission
    5.3 Permissions

    6. On acceptance and publication
    6.1 SAGE Production
    6.2 Online First publication
    6.3 Access to your published article
    6.4 Promoting your article

    7. Further information
    7.1 Appealing the publication decision


    1. What do we publish?

    1.1 Aims & Scope
    Journal of Pharmacy Practice is a peer-reviewed journal that offers practicing pharmacists in-depth useful reviews and research trials and surveys of new drugs and novel therapeutic approaches, pharmacotherapy reviews and controversies, pharmacokinetics, drug interactions, drug administration, adverse drug events, medication safety, pharmacy education, and other pharmacy practice topics.

    1.2 Article types

    • Pharmacy Practice Review Articles
      a. Abstract (250 word limit)
      b. Keywords (5 keywords limit)
      c. References (100 limit)
      d. Word Count (5,000)
    • Drug or Therapeutic Review Articles
      a. Abstract (250 word limit)
      b. Keywords (5 keywords limit)
      c. References (150 limit)
      d. Word Count (5,000)
    • Continuing Education Articles
      a. Abstract (250 word limit)
      b. Keywords (5 keywords limit)
      c. Goals and objectives (7 limit)
      d. References (150 limit)
      e. Word Count (5,000)
    • Research Reports
      a. Structured Abstract (250 word limit) (to include Background, Objective, Methods, Results, Conclusion)
      b. Keywords (5 keywords limit)
      c. References (100 limit)
      d. Word Count (5,000)
    • Pharmacy Experiential Education
      a. Abstract (250 word limit)
      b. Keywords (5 keywords limit)
      c. References (100 limit)
      d. Word Count (4,000)
    • Adverse Drug Event Case Reports
      a. Abstract (250 word limit)
      b. Keywords (5 keywords limit)
      c. References (50 limit)
      d. Word Count (2,500)
    • Case Reports or Case Studies
      a. Abstract (250 word limit)
      b. Keywords (5 keywords limit)
      c. References (50 limit)
      d. Word Count (2,500)
    • Biomedical Communications or Informatics Reviews
      a. No Abstract
      b. Keywords (5 keywords limit)
      c. References (10 limit)
      d. Word Count (1,500)
    • Editorial or Commentary
      a. Abstract (150 word limit)
      b. Keywords (5 keywords limit)
      c. References (20 limit)
      d. Word Count (1,500)
    • Letters to the Editor
      a. No Abstract
      b. Keywords (5 keywords limit)
      c. References (10 limit)
      d. Word Count (750)

    1.3 Writing your paper
    The SAGE Author Gateway has some general advice on how to get published, plus links to further resources.

    File Downloads:

    1.3.1 Make your article discoverable
    For information and guidance on how to make your article more discoverable, visit our Gateway page on How to Help Readers Find Your Article Online


    2. Editorial policies

    2.1 Peer review policy
    JPP adheres to a rigorous double-anonymized reviewing policy in which the identity of both the reviewer and author are always concealed from both parties.

    SAGE does not permit the use of author-suggested (recommended) reviewers at any stage of the submission process, be that through the web-based submission system or other communication. Reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Our policy is that reviewers should not be assigned to a paper if:

    • The reviewer is based at the same institution as any of the co-authors
    • The reviewer is based at the funding body of the paper
    • The author has recommended the reviewer
    • The reviewer has provided a personal (e.g. Gmail/Yahoo/Hotmail) email account and an institutional email account cannot be found after performing a basic Google search (name, department and institution). 

    2.2 Authorship
    Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

    The list of authors should include all those who can legitimately claim authorship. This is all those who:

    1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
    2. Drafted the article or revised it critically for important intellectual content,
    3. Approved the version to be published,
    4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

    2.3 Acknowledgements
    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    Please supply any personal acknowledgements separately to the main text to facilitate anonymous peer review.

    2.3.1 Third party submissions

    Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:

    • Disclose this type of editorial assistance – including the individual’s name, company and level of input
    • Identify any entities that paid for this assistance
    • Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.

    Where appropriate, SAGE reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.

    2.3.2 Writing assistance
    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.

    2.4 Funding
    JPP requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

    2.5 Declaration of conflicting interests
    It is the policy of JPP to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations here

    2.6 Research ethics and patient consent
    Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

    For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants

    2.7 Clinical trials
    JPP conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

    2.8 Reporting guidelines
    The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives

    2.9. Research Data

    The journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the SAGE Research Data policy pages.

    Subject to appropriate ethical and legal considerations, authors are encouraged to:

    • share your research data in a relevant public data repository
    • include a data availability statement linking to your data. If it is not possible to share your data, we encourage you to consider using the statement to explain why it cannot be shared.
    • cite this data in your research


    3. Publishing policies

    3.1 Publication ethics
    SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway

    3.1.1 Plagiarism
    and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    3.1.2 Prior publication
    If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.

    3.2 Contributor’s publishing agreement      
    Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit the SAGE Author Gateway

    3.3 Open access and author archiving

    Journal of Pharmacy Practice offers optional open access publishing via the SAGE Choice programme. For more information on Open Access publishing options at SAGE please visit SAGE Open Access. For information on funding body compliance, and depositing your article in repositories, please visit SAGE’s Author Archiving and Re-Use Guidelines and Publishing Policies.



    4. Preparing your manuscript for submission

    4.1 Formatting
    The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

    4.2 Artwork, figures and other graphics
    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines  

    Charges for color figures: $800.00 for the first figure and $200.00 for each additional figure. Color reproduction in the online PDF is free of charge.

    4.3 Supplemental material
    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc.) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplemental files

    4.4 Reference style
    References must begin on a separate page. They must be numbered consecutively in the order in which they appear in the text by superscript Arabic numerals. References should be typed in the style adopted by the National Library of Medicine and used in Index Medicus with the exception that only the first 3 authors (last name and up to 2 initials) are listed. For example, a standard journal article with more than 3 authors should be listed as shown below. References should not include any unpublished observations or personal communications.

    1. Schoni MH, Casaulta-Aebischer C, Martinet LV, et al. Nutrition and lung function in cystic fibrosis patients: review. Clin Nutr. 2000;19:79-85.

    4.5 English language editing services
    Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.


    5. Submitting your manuscript
    JPP is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit to login and submit your article online.

    IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.  For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

    5.1 ORCID
    As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.

    The collection of ORCID IDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID ID you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID ID will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID ID is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.

    If you do not already have an ORCID ID please follow this link to create one or visit our ORCID homepage to learn more.

    5.2 Information required for completing your submission
    You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. The affiliation listed in the manuscript should be the institution where the research was conducted. If an author has moved to a new institution since completing the research, the new affiliation can be included in a manuscript note at the end of the paper. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

    5.3 Permissions
    Please also ensure that you have obtained any necessary permission
    from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. A permission form can be found at the end of these guidelines. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the SAGE Author Gateway


    6. On acceptance and publication

    6.1 SAGE Production
    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will be made available to the corresponding author via our editing portal SAGE Edit or by email, and corrections should be made directly or notified to us promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorizing the change.

    6.2 Online First publication
    Online First allows final articles (completed and approved articles awaiting assignment to a future issue) to be published online prior to their inclusion in a journal issue, which significantly reduces the lead time between submission and publication. Visit the SAGE Journals help page for more details, including how to cite Online First articles.

    6.3 Access to your published article
    SAGE provides authors with online access to their final article.

    6.4 Promoting your article
    Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.


    7. Further information
    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the JPP editorial office as follows:

    Henry Cohen, MS, PharmD, BCPP, BCGP
    Editor in Chief, JPP
    Tel: (718) 604-5373

    7.1 Appealing the publication decision
    Editors have very broad discretion in determining whether an article is an appropriate fit for their journal. Many manuscripts are declined with a very general statement of the rejection decision. These decisions are not eligible for formal appeal unless the author believes the decision to reject the manuscript was based on an error in the review of the article, in which case the author may appeal the decision by providing the Editor with a detailed written description of the error they believe occurred.

    If an author believes the decision regarding their manuscript was affected by a publication ethics breach, the author may contact the publisher with a detailed written description of their concern, and information supporting the concern, at

      Individual Subscription, Print Only

      Individual Subscription, Combined (Print & E-access)

      Institutional Subscription, E-access

      Institutional Backfile Purchase, E-access (Content through 1998)

      Institutional Subscription & Backfile Lease, E-access Plus Backfile (All Online Content)

      Institutional Subscription, Print Only

      Institutional Subscription, Combined (Print & E-access)

      Institutional Subscription & Backfile Lease, Combined Plus Backfile (Current Volume Print & All Online Content)

      Individual, Single Print Issue

      Institutional, Single Print Issue